News and Trends 18 Sep 2018
Update: French Biotech Raises €22M for a Gene Therapy Trial in Retinitis Pigmentosa
Update (18/09/2018): Horama has increased the total raised in its Series B fundraising to €22.5M, with the Belgian fund V-Bio Ventures joining the team of investors backing the company. The funds will be mainly directed at developing Horama’s gene therapy for retinitis pigmentosa. Published on 08/10/2017 Horama has raised a second fundraising round that will support […]